Listen
ARGANOVA
-
Opinions on drugs -
Posted on
Nov 16 2011
- Updated on
Dec 07 2011
Reason for request
Inclusion on the list of medicines approved for hospital use.
-
Clinical Benefit
| Substantial |
The actual benefit of ARGANOVA (argatroban) is substantial. |
Clinical Added Value
| no clinical added value |
ARGANOVA does not provide an improvement in actual benefit (IAB level V) in the treatment of adult patients with heparin-induced thrombocytopenia (HIT) type II, requiring parenteral anti-thrombotic treatment. |
English version
Contact Us
Évaluation des médicaments
